Global /United States /Healthcare /Drug Manufacturers - General /ORMP

Oramed Pharmaceuticals Inc.

ORMP

• NASDAQ: ORMP • Delayed

3.84USD -4.7%

As of 14 June 2026, Oramed Pharmaceuticals Inc. has a market cap of $155.31M USD, ranking #22675 globally and #3622 in the United States. It ranks #2035 in the Healthcare sector, and #730 in the Drug Manufacturers - General industry.

Global Rank

22675

Country Rank

3622

Sector Rank

2035

Industry Rank

730

Key Stats

Market Cap

$155.31MUSD

Enterprise Value

$23.9MUSD

Revenue (TTM)

$2.0MUSD

EBITDA (TTM)

-$14.97MUSD

Net Income (TTM)

$63.24MUSD

Profit Margin

3K%

PE Ratio

2.7

PS Ratio

78.7

PB Ratio

0.8

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Nadav Kidron open_in_new

Employees

Founded

2002

Website

oramed.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.7%	4.7%	22%	16%	71%	41%	80%	78%	-63%

News

ORMP Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	ORMP Oramed Pharmaceuticals Inc ISIN: US68403P2039 Shares Out.: Shares Outstanding: 40.926M¹ Shares Float: 31.723M² TV: TradingView: NASDAQ: ORMP SA: Stock Analysis: NASDAQ: ORMP YF: Yahoo Finance: ORMP GF: Google Finance: NASDAQ: ORMP NQ: NASDAQ: ORMP BA: Barron's: ORMP MS: Morningstar: XNAS: ORMP	3.84 USD	TV: TradingView: NASDAQ: ORMP SA: Stock Analysis: NASDAQ: ORMP YF: Yahoo Finance: ORMP GF: Google Finance: NASDAQ: ORMP NQ: NASDAQ: ORMP BA: Barron's: ORMP MS: Morningstar: XNAS: ORMP
Tel Aviv Stock Exchange (TLV) MIC: XTAE	ORMP Oramed Pharmaceuticals Inc ISIN: US68403P2039 TV: TradingView: TASE: ORMP SA: Stock Analysis: TLV: ORMP YF: Yahoo Finance: ORMP.TA GF: Google Finance: TLV: ORMP BA: Barron's: ORMP MS: Morningstar: XTAE: ORMP	1,169 ILA	TV: TradingView: TASE: ORMP SA: Stock Analysis: TLV: ORMP YF: Yahoo Finance: ORMP.TA GF: Google Finance: TLV: ORMP BA: Barron's: ORMP MS: Morningstar: XTAE: ORMP

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 490K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 352K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 232K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 176K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 96K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 76K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 207K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 186K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 177K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 117K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 71K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 70K%	14.6	United Kingdom

chevron_leftBack